FY2025 EPS Estimates for Humana Cut by Leerink Partnrs

Humana Inc. (NYSE:HUM) – Leerink Partnrs dropped their FY2025 EPS estimates for Humana in a report released on Tuesday, February 11th. Leerink Partnrs analyst W. Mayo now forecasts that the insurance provider will post earnings of $16.51 per share for the year, down from their previous forecast of $16.86. The consensus estimate for Humana’s current full-year earnings is $16.11 per share. Leerink Partnrs also issued estimates for Humana’s Q2 2026 earnings at $5.51 EPS, Q4 2026 earnings at ($1.08) EPS, FY2026 earnings at $15.81 EPS, FY2027 earnings at $27.79 EPS, FY2028 earnings at $36.69 EPS and FY2029 earnings at $45.87 EPS.

Other equities research analysts have also recently issued reports about the company. Bank of America upgraded Humana from an “underperform” rating to a “neutral” rating and lifted their target price for the stock from $247.00 to $308.00 in a research note on Wednesday, November 6th. Piper Sandler raised their price target on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a report on Wednesday, January 15th. TD Cowen boosted their price objective on shares of Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Royal Bank of Canada restated an “outperform” rating and issued a $283.00 target price on shares of Humana in a research note on Wednesday. Finally, Barclays raised their price objective on shares of Humana from $253.00 to $255.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 22nd. Nineteen analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $292.26.

Humana Price Performance

Shares of NYSE HUM opened at $259.93 on Thursday. The stock’s 50 day moving average price is $272.44 and its 200-day moving average price is $295.47. The company has a market capitalization of $31.30 billion, a PE ratio of 23.02, a PEG ratio of 2.11 and a beta of 0.56. Humana has a twelve month low of $213.31 and a twelve month high of $406.46. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67.

Humana (NYSE:HUM) last released its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 13.20% and a net margin of 1.18%.

Hedge Funds Weigh In On Humana

A number of institutional investors have recently bought and sold shares of HUM. AMF Tjanstepension AB grew its holdings in Humana by 166.8% in the third quarter. AMF Tjanstepension AB now owns 40,051 shares of the insurance provider’s stock worth $12,686,000 after purchasing an additional 25,041 shares during the period. Exchange Traded Concepts LLC purchased a new position in Humana in the 3rd quarter worth about $348,000. Swedbank AB raised its holdings in shares of Humana by 3.0% during the third quarter. Swedbank AB now owns 105,976 shares of the insurance provider’s stock valued at $33,567,000 after purchasing an additional 3,085 shares during the last quarter. Bleakley Financial Group LLC grew its holdings in shares of Humana by 14.8% in the third quarter. Bleakley Financial Group LLC now owns 1,841 shares of the insurance provider’s stock worth $583,000 after acquiring an additional 237 shares during the period. Finally, Sumitomo Mitsui DS Asset Management Company Ltd increased its position in shares of Humana by 1.3% during the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 13,963 shares of the insurance provider’s stock valued at $4,423,000 after purchasing an additional 179 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

Insider Activity

In related news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.32% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.